EXINI Diagnostics AB

Our Vision
We aim to empower patients for better healthcare with Artificial Intelligence.
AI in Healthcare is Our Passion
We develop advanced medical devices powered with Artificial Intelligence.
Solutions to Real Problems
We employ Artificial Intelligence for objective and clinically relevant analysis of medical images.
From Lund to New York
We are partnered with a global leader in theranostic medicine to target and treat cancer.

News!

EXINI Diagnostic AB receives FDA clearance for cloud aBSI in United States.
The cloud based neural network of aBSI device automatically segments the different anatomical regions of the skeleton followed by detection and classification of lesions in bone scan of prostate cancer patients. The aBSI has been shown to be an objective measure of the quantitative change in disease burden and is a prognostic biomarker in patients with metastatic prostate cancer. In August, the Company received 510(k) clearance from the FDA to market their cloud-based version of Automated Bone Scan Index (aBSI) product in the U.S (K191262). A 510(k) filing is a premarket submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective as compared to a legally marketed device that is not subject to a Premarket Approval application. The clearance of a cloud based software as a medical device is an essential step towards the further development and clearance of the PSMA(PyL) AI product.

“The FDA clearance is a validation of our approach in using AI technology to solve clinically relevant problems in disease management of patients with prostate cancer” said Aseem Anand, Vice President and Site Manager of EXINI Diagnostics AB, Sweden.
Collaboration with Veterans Affairs in United States on the AI Research Program for Medical Image Analysis
On July 25, 2019, EXINI a fully owned subsidiary of Progenics Pharmaceuticals, entered into collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), United States, on its AI research program. The collaborative program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of Veterans with prostate cancer.
Read More
EXINI PSMA-AI device
highlighted at SNMMI 2019
June 24, at Anaheim, CA - EXINI team presented the performance of PSMA-AI device in an independent and prospectively defined study. The work was selected for an Oral presentation at SNMMI2019 and was picked for discussion in the highlight summary session. 

In a prospectively defined independent study, the data demonstrated that the AI-device assisted reads were better than manual only read in terms of speed, precision and diagnostic accuracy. The data is part of continual effort to enhance the clinical utility of imaging biomarkers with standardized and accurate assessment. 

Our focus remains on using technology to address clinically relevant questions for treatment management of Prostate Cancer. 
Read More
EXINI Agreement with
FUJIFILM Toyama Chemical Co. in Japan
As of June 18, 2019, EXINI, a wholly owned subsidiary of Progenics Pharmaceuticals Inc. has entered into a licence and transfer agreement with FUJIFILM Toyama Chemical Co, Ltd. (FFTC) for the rights to Automated Bone Scan Index (aBSI) product in Japan for use under the name BONENAVI.

aBSI has become an integral component of prostate cancer practice patterns in Japan, and we are delighted to continue our relationship with FFTC, a leading Japanese pharmaceutical and diagnostic company, to offer this optimized and quick response technology solution to support physician treatment decisions for prostate cancer patients.
Read More

aBSI

Read about our automatic bone scan index software.

Join Our Team

Find our open positions and send us your application.

Find Us at the Top of Lund

Get in contact with us.

EXINI

Find out more about EXINI and what we do.